pf-00258210
Small moleculeexperimental
Clinical trial activity
10 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2005 (NCT02256735)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Alpha-2b adrenergic receptorINHIBITOR
ADRA2B inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pf-00258210
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02385071 | Phase 1 | Apr 1, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01897389 | Phase 1 | Jul 1, 2013 | Johnson and Johnson |
| NCT01841489 | Phase 1 | May 1, 2013 | Gilead Sciences |
| NCT01272375 | Phase 1 | Jan 1, 2011 | Pfizer |
| NCT01181700 | Phase 1 | Oct 1, 2010 | Pfizer |
| NCT01244035 | Phase 1 | Aug 1, 2010 | Merck |
| NCT01043276 | Phase 1 | Jan 1, 2010 | Pfizer |
| NCT00946842 | Phase 1 | Aug 1, 2009 | Tibotec |
| NCT00928278 | Phase 1 | Jul 1, 2009 | Pfizer |
| NCT02256735 | Phase 1 | Aug 1, 2005 | Boehringer Ingelheim |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 1 | 2009 |
| Johnson and Johnson | For profit | 2 | 2 | 1 | 2013 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2005 |
| Gilead Sciences | For profit | 1 | 1 | 1 | 2013 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2015 |
| Merck | For profit | 1 | 1 | 1 | 2010 |
| Tibotec | For profit | 1 | 1 | 1 | 2009 |
7 organizations
Page 1 / 1